Mendus AB (“Mendus” publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, today announced its participation in the following upcoming investor and industry conferences:
Redeye Growth Day
Virtual, June 1, 2023
Mendus CEO Erik Manting will participate in a live Q&A session on June 1st. Further details including the on-demand corporate presentation are available via:
https://www.redeye.se/events/871323/redeye-growth-day
BIO International Convention
Boston, USA, June 5-8, 2023
Erik Manting, CEO of Mendus, will attend the conference.
https://www.bio.org/events/bio-international-convention
EHA2023 Hybrid Congress
Frankfurt, Germany, and Virtual, June 8-11, 2023
Mendus to present updates on immunomonitoring data from ADVANCE II trial and progress on the development of its NK cell therapy program.
https://ehaweb.org/congress/eha2023-hybrid-congress/eha2023/
FOR MORE INFORMATION, PLEASE CONTACT:
Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
INVESTOR RELATIONS
Corey Davis
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
E-mail: cdavis@lifesciadvisors.com
MEDIA RELATIONS
Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu
ABOUT MENDUS AB (PUBL)
Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/
Attachment
